How to Get BHRT Online: A 5-Step Guide

What BHRT Actually Is (and Is Not)

Bioidentical hormone replacement therapy uses hormones that are chemically identical in molecular structure to the estrogen, progesterone, and testosterone your ovaries naturally produce. The term sounds like a marketing word, and the wellness industry has certainly misused it, but the underlying science is real.

Some BHRT products are FDA-approved. Estradiol patches, gels, sprays, and vaginal rings are regulated and tested for potency and purity. Oral micronized progesterone (Prometrium) is also FDA-approved and considered bioidentical. The controversy around BHRT mostly concerns custom-compounded preparations, where a pharmacy mixes a unique formulation to a clinician's specification. The FDA does not evaluate compounded preparations for safety or efficacy, and dosing reliability varies between batches.

Understanding this distinction before you start the process protects you from providers who oversell unproven multi-hormone compounded pellets as categorically superior to well-studied FDA-approved options.

How BHRT Differs from Conventional HRT

The phrase "conventional HRT" typically refers to products that include synthetic progestins (such as medroxyprogesterone acetate) or conjugated equine estrogens. Bioidentical formulations use 17-beta-estradiol and micronized progesterone instead. Whether this difference changes clinical outcomes is still debated. The E3N cohort study, published in Climacteric, found a lower breast cancer signal with micronized progesterone compared to synthetic progestins, though randomized trial data specifically comparing the two in large populations are limited. Women have been under-represented in head-to-head RCTs comparing bioidentical versus synthetic progestins, and that evidence gap should inform any shared decision-making conversation with your provider.

FDA-Approved Bioidentical Options at a Glance

| Hormone | Product Examples | Route | |---|---|---| | Estradiol | Vivelle-Dot, Climara, Divigel, Evamist | Patch, gel, spray | | Micronized progesterone | Prometrium 100 mg, 200 mg | Oral capsule | | Estradiol vaginal | Vagifem, Imvexxy, Estring | Tablet, insert, ring | | Testosterone (off-label) | Androgel (compounded female dose) | Gel |

Step 1: Confirm Your Symptoms and Life Stage

Before you contact any provider, spend a week tracking your symptoms. This is not optional admin. Providers prescribe based on symptom burden and lab context, and a clear picture of what you are experiencing shortens the intake process considerably.

Recognizing Perimenopause

Perimenopause typically begins in the mid-to-late 40s, though it can start earlier. The average age of menopause in the United States is 51.4 years, meaning the transition phase often starts around 45 to 48. Characteristic symptoms include:

• Irregular cycles (shorter or longer, heavier or lighter)
• Hot flashes and night sweats (vasomotor symptoms)
• Sleep disruption not explained by other causes
• Mood changes, irritability, or low-grade depression
• Brain fog or difficulty concentrating
• Joint aches
• Vaginal dryness or pain with intercourse
• Low libido

In perimenopause, your FSH and estradiol levels fluctuate dramatically day to day. A single lab draw may look normal even when you feel symptomatic. A good telehealth provider will understand this and will not dismiss you because one estradiol value falls in the "normal" range.

Post-Menopause

After 12 consecutive months without a period, you are post-menopausal. Symptoms often persist for years. The Study of Women's Health Across the Nation (SWAN) found that vasomotor symptoms lasted a median of 7.4 years from onset, longer than previously assumed. Post-menopausal women starting BHRT within 10 years of their final menstrual period and before age 60 fall within the timing window that The Menopause Society 2023 Position Statement identifies as the period when benefits of hormone therapy most clearly outweigh risks.

Surgical Menopause

Women who have had a bilateral oophorectomy (removal of both ovaries) experience an abrupt drop in estrogen regardless of age. Symptoms are often more severe than in natural menopause. If this applies to you, flag it explicitly during intake because dosing requirements and urgency differ.

Step 2: Choose a Vetted Telehealth Provider

This step carries the most risk of a poor outcome. The telehealth market expanded rapidly after 2020, and not every platform offering hormone therapy employs clinicians with genuine women's-health expertise.

What to Look For

A trustworthy online BHRT provider will:

• Employ licensed physicians, NPs, or PAs with documented training in women's health, reproductive endocrinology, or menopause medicine
• Require laboratory testing before prescribing, not after
• Offer FDA-approved options as a first-line choice, with compounded options as an informed second choice when appropriate
• Conduct a thorough medical history that includes cancer history, clotting history, liver disease, and cardiovascular risk
• Provide follow-up appointments at 6 to 12 weeks, not disappear after sending a prescription

Red Flags

Avoid any platform that:

• Prescribes based on a symptom quiz alone with no lab work
• Defaults immediately to compounded pellets without discussing FDA-approved alternatives
• Uses hormone panel "optimization" language without reference to guideline-based dosing
• Claims to treat every condition with a single compounded multi-hormone formula
• Cannot tell you which clinician is responsible for your prescription

The WomanRx BHRT Provider Evaluation Framework applies four criteria to any online provider you are considering: credential transparency (can you find the clinician's license?), lab-first policy (do they require baseline testing?), guideline alignment (do they cite ACOG or The Menopause Society?), and follow-up commitment (is ongoing monitoring built into the cost?). Score each criterion before you book.

Step 3: Complete Your Medical Intake

Once you have chosen a provider, the intake process begins. This is longer than a typical primary-care visit. Expect 30 to 60 minutes for a thorough telehealth evaluation.

What the Clinician Needs to Know

Your clinician will ask about:

Menstrual and reproductive history. Date of last menstrual period, cycle regularity changes, any prior hormone use (including hormonal contraceptives), history of fertility treatments.

Personal cancer history. Hormone-sensitive cancers, particularly breast and endometrial cancer, change whether BHRT is appropriate and which formulation is safest. Women with a personal history of ER/PR-positive breast cancer should have this conversation with their oncologist before proceeding.

Cardiovascular and clotting history. Prior DVT, PE, stroke, or MI affects route-of-administration decisions. Transdermal estradiol does not carry the same first-pass liver metabolism that oral estrogen does, and observational data suggest a lower thrombotic risk with the transdermal route. For women with a history of clotting disorders, transdermal is almost always preferred.

Family history. First-degree relatives with breast cancer, ovarian cancer, or early cardiovascular disease.

Current medications and supplements. Several drugs interact with estrogen metabolism, including certain antiepileptics, rifampin, and St. John's Wort.

Mental health history. Perimenopause is a neurobiological window of increased vulnerability to depression. ACOG Practice Bulletin 141 notes that perimenopausal women are at elevated risk for depressive symptoms, and some will benefit from antidepressant therapy in combination with or instead of hormone therapy.

Breast Exam and Mammography

A responsible telehealth provider will confirm that you are current on age-appropriate mammography screening before initiating systemic estrogen. The American College of Radiology recommends annual mammograms starting at age 40 for average-risk women. If you have not had one recently, you may be asked to schedule one concurrently.

Step 4: Get Your Labs Drawn

Lab work is the foundation of safe BHRT prescribing. A provider who skips this step is not practicing responsibly.

Core Hormone Panel

Most BHRT-focused providers will order:

• Estradiol (E2): Baseline level; remember that in perimenopause this fluctuates widely
• FSH: Elevated FSH (generally above 25 to 30 IU/L) supports a menopausal picture, though values vary
• LH: Often ordered alongside FSH
• Total and free testosterone: Relevant if low libido or fatigue is a primary complaint
• SHBG (sex hormone-binding globulin): Affects how much free hormone is biologically active; oral estrogen raises SHBG, which may suppress free testosterone
• Progesterone: Useful if cycle irregularity is the main issue and to confirm ovulation in perimenopausal women
• DHEA-S: Adrenal androgen precursor, often included in broader panels
• Thyroid panel (TSH, free T4): Thyroid dysfunction mimics many menopause symptoms; postpartum thyroiditis affects up to 10% of women in the first year after delivery and should not be mistaken for early perimenopause

Metabolic and Safety Labs

• Fasting lipid panel
• Fasting glucose and HbA1c
• Liver function tests (especially if oral estrogen is planned)
• Complete blood count
• Blood pressure (self-reported or from a recent clinic visit)

Where to Get Labs

Most telehealth providers partner with national lab networks (Quest, LabCorp, Labcorp at-home) and send an electronic order directly to a draw site near you. Some offer at-home fingerstick or dried blood spot kits, though venipuncture results are generally more accurate for hormone panels at low levels. Results typically return within two to five business days.

Step 5: Receive and Start Your Prescription

Once your clinician reviews your labs alongside your symptom picture, she or he will recommend a starting regimen. Expect a video or phone follow-up to walk through the recommendation before anything is sent to a pharmacy.

Common Starting Regimens by Life Stage

Perimenopausal women (still cycling, or <12 months since last period): Low-dose estradiol patch (0.025 to 0.05 mg/day) with cyclic micronized progesterone (200 mg orally for 12 to 14 days per cycle) is a common approach that allows continued cycle tracking while managing symptoms. ACOG supports hormone therapy as an appropriate option for perimenopausal women with bothersome vasomotor symptoms.

Post-menopausal women with a uterus: Continuous combined therapy is standard: daily estradiol plus daily low-dose micronized progesterone (100 mg) to protect the endometrium. Unopposed estrogen in women with an intact uterus increases endometrial cancer risk, which is why progesterone is non-negotiable in this group.

Post-menopausal women without a uterus (post-hysterectomy): Estrogen alone is appropriate. No progesterone is needed. This is one of the clearest risk-benefit scenarios in menopause medicine.

Women with primarily genitourinary symptoms (GSM): Low-dose vaginal estradiol (Vagifem 10 mcg, Imvexxy 4 mcg or 10 mcg) or vaginal estrogen cream addresses vaginal dryness, recurrent UTIs, and dyspareunia with minimal systemic absorption. The Menopause Society states that low-dose vaginal estrogen is safe for most women, including many breast cancer survivors, based on current evidence.

Testosterone for Women

Off-label low-dose testosterone is increasingly recognized for hypoactive sexual desire disorder (HSDD) in post-menopausal women. A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology found that testosterone improved sexual function scores significantly compared to placebo across 36 trials. No FDA-approved female testosterone product exists in the U.S.; compounded gels or creams at one-tenth the male dose (approximately 0.5 to 1 mg/day) are typically used. This is an area where evidence in women is specifically growing but remains thinner than the estrogen literature.

What Happens at the Follow-Up Appointment

A follow-up at 6 to 12 weeks is standard of care. Your clinician will ask about symptom response, side effects (breast tenderness, bloating, spotting), and may repeat estradiol and progesterone levels to confirm therapeutic range. Dose adjustments are common in the first three to six months. Annual follow-ups with repeat labs and continued mammography are expected thereafter.

Pregnancy, Lactation, and Contraception: What Every Perimenopausal Woman Needs to Know

This section applies to any woman who has not yet reached confirmed menopause (12 consecutive months without a period).

Pregnancy Risk in Perimenopause

Perimenopause does not equal infertility. Ovulation is irregular but not absent. ACOG advises that women in perimenopause should use contraception until they have reached menopause if they do not wish to conceive. Unintended pregnancy rates in women aged 40 to 44 are lower than in younger decades but not zero.

BHRT Is Contraindicated in Pregnancy

Systemic estrogen and progesterone supplementation is not appropriate during pregnancy. If you are perimenopausal and starting BHRT, your provider must confirm that you are using reliable non-hormonal contraception or a progestin-based method compatible with the BHRT regimen. Copper IUDs (Paragard) and barrier methods are common choices. Hormonal IUDs (Mirena) provide endometrial protection and contraception simultaneously and may reduce or eliminate the need for separate progesterone in some BHRT protocols, though this is an off-label use and requires individualized assessment.

If You Are Trying to Conceive

Women with perimenopause-level symptoms who are still trying to conceive should not use systemic BHRT as prescribed for menopause management. This is a conversation for a reproductive endocrinologist, not a general telehealth menopause platform. Low-dose vaginal estrogen for GSM may be considered under specialist guidance, but systemic therapy for ovarian stimulation is a distinct clinical domain.

Lactation

Systemic estrogen suppresses prolactin and can reduce milk supply. Breastfeeding women should not use systemic estrogen-containing BHRT. Vaginal low-dose estrogen has minimal systemic absorption, but data on transfer into breast milk remain limited. Any postpartum woman considering hormone therapy should disclose breastfeeding status to her provider and confirm safety on a product-by-product basis.

Who BHRT Online Is Right For (and Who Should Pause)

Good Candidates for Online BHRT

• Women 40 or older with bothersome perimenopausal or menopausal symptoms affecting daily function or sleep
• Post-menopausal women within 10 years of their last period and under age 60 (the timing window with the most favorable evidence)
• Women with surgical menopause at any age who need hormone support
• Women whose primary-care providers have been dismissive of their symptoms and who want a specialist-level evaluation

Situations Where In-Person Evaluation Is Safer First

• Personal history of estrogen receptor-positive breast cancer (requires oncology sign-off)
• Active or recent DVT, PE, or stroke
• Undiagnosed abnormal uterine bleeding (needs endometrial evaluation before estrogen is started)
• Liver disease
• Untreated hypertriglyceridemia (oral estrogen can raise triglycerides significantly; transdermal does not carry the same risk, but specialist review is wise)
• Desire to conceive (reproductive endocrinology referral needed)

BHRT and Related Women's-Health Conditions

PCOS

Women with polycystic ovary syndrome reach perimenopause with a different hormonal baseline. They often have higher androgen levels and irregular cycles throughout reproductive years, making symptom recognition harder. SHBG is often suppressed chronically. Menopausal transition in PCOS may present differently, and a 2022 review in Fertility and Sterility noted that women with PCOS may experience later menopause on average but still experience vasomotor symptoms. BHRT decisions in this population benefit from an endocrinologist or reproductive endocrinologist familiar with PCOS physiology.

Thyroid Conditions

Oral estrogen increases thyroid-binding globulin, which can increase the levothyroxine dose needed in women with hypothyroidism. This effect is not seen with transdermal estradiol. If you take levothyroxine and are starting BHRT, ensure your TSH is rechecked six to eight weeks after starting oral estrogen.

Osteoporosis and Bone Health

Estrogen deficiency drives bone loss. The Women's Health Initiative trial showed that conjugated equine estrogen plus MPA reduced hip fracture risk by 34% over 5.2 years. Bioidentical estradiol is expected to confer similar bone protection, though the WHI used a specific synthetic formulation. For women in early menopause with low bone density, BHRT may serve both symptom relief and skeletal protection goals simultaneously.